Premarket trading on Tuesday saw sharp moves across several high-profile names, driven by defense contract news, product and technology updates, earnings results, rating changes and fresh analyst coverage. Boeing rose as it secured a major U.S. defense development agreement, while Concentrix and Cal-Maine Foods fell after results and guidance disappointed investors. Elsewhere, Robinhood advanced on plans to roll out an in-app AI agent and expanded trading features, and Moderna slid following a Citi downgrade.
Key takeaways
- Boeing shares rose about 2% after the company won a contract tied to the next generation of U.S. fighter jet development.
- Concentrix shares fell roughly 9.5% after fiscal third-quarter revenue and non-GAAP guidance came in below expectations.
- Robinhood gained around 2% on announcements including an in-app AI agent and plans to introduce 24/7 trading for certain stocks.
- Moderna dropped more than 6% following a Citi downgrade to sell.
- Cal-Maine Foods declined over 6.5% after reporting a wider-than-expected loss for its fiscal first quarter.
Defense, AI and product expansion move stocks
Boeing was among the strongest premaket performers after the company secured a deal with the U.S. defense department to develop the next generation of fighter jets. The contract is described as a $20 billion program for Boeing to build the Sixth-Generation F/A-XX Strike Fighter, a development that helped lift sentiment around the company’s long-term defense pipeline. Northrop Grumman, which was reportedly also in contention, fell about 3.5% as investors rotated away from the perceived competitive outcome.
Robinhood advanced about 2% as investors reacted to a broader push into AI-enabled tools for retail trading. The company said it plans to introduce an in-app AI agent for its traders, alongside the rollout of 24/7 trading for certain U.S. stocks. Robinhood also disclosed plans to introduce perpetual futures to its U.S. users soon, a move that could potentially expand product variety and trading engagement, though timing and adoption will likely be key in the near term.
Earnings and guidance disappoint: Concentrix and Cal-Maine Foods
Concentrix dropped nearly 9.5% after it reported fiscal third-quarter results that came in slightly below expectations. The company’s non-GAAP earnings per share and revenue guidance for the current quarter were also described as below what analysts were expecting, according to analysts polled by FactSet. On its earnings call, Concentrix said its AI transition is putting pressure on revenues, pointing to near-term cost or operational impacts as the company shifts workflows and capabilities to align with artificial intelligence-driven delivery.
Cal-Maine Foods fell more than 6.5% after reporting a fiscal first-quarter loss that was wider than expected. The company reported a loss of $1.26 per share, compared with analysts’ expectations for a loss of 77 cents per share, according to FactSet. For egg producers, investor focus often centers on pricing power and cost controls; a substantially larger-than-expected loss can quickly raise concerns about demand, pricing trends, and margin durability.
Rating change and valuation concerns weigh on Moderna
Moderna declined more than 6% after Citi downgraded the stock to sell. Citi also set a price target that is described as 60% below the stock’s closing price on Tuesday, arguing the company’s current valuation cannot be justified. Downgrades of high-profile biotech stocks can pressure shares not only through the immediate sentiment effect, but also by reshaping expectations for future catalysts and risk-reward, particularly when the market is evaluating progress versus timelines.
Analyst initiation and growth linkage lift FormFactor
FormFactor rose about 1% after Deutsche Bank initiated coverage of the semiconductor testing company with a buy rating. Analysts highlighted that FormFactor is positioned to benefit from increasing chip testing intensity. The coverage also pointed to the company’s role as a second source of probe cards used for Nvidia GPUs at TSMC, a detail that frames FormFactor’s revenue outlook around both platform share and manufacturing demand.
What to watch next
With several catalysts hitting in quick succession—contract activity, AI product updates, earnings results, and rating actions—investors will likely look for follow-through in the regular session as markets absorb new guidance and outlook changes. Next, traders will be watching for additional commentary from companies that guided down revenues, any clarification around AI transition timelines, and broader reaction to biotechnology valuations after the Citi downgrade. The coming session’s focus may also shift to forthcoming earnings from other consumer, semiconductor, and defense-adjacent names, as investors recalibrate expectations for the quarter.
